









Markets
/
Stocks
/
nasdaq-zyme
/

Zymeworks Inc

ZYME



View Detailed Chart

26.860USD

+0.070+0.26%

Close 12/24, 13:00（ET）Quotes delayed by 15 min

2.03BMarket Cap

LossP/E TTM



Zymeworks Inc

26.860

+0.070+0.26%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+0.26%

5 Days

+1.74%

1 Month

+2.60%

6 Months

+111.33%

Year to Date

+83.47%

1 Year

+89.96%

View Detailed Chart

TradingKey Stock Score of Zymeworks Inc

Currency: USD Updated: 2025-12-24

Key Insights

Zymeworks Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 12/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Zymeworks Inc's Score

Industry at a Glance

Industry Ranking

12 / 404

Overall Ranking

62 / 4562

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

34.500

Target Price

+30.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Zymeworks Inc Highlights

StrengthsRisks

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Growing

The company is in a growing phase, with the latest annual income totaling USD 76.30M.

Undervalued

The company’s latest PE is -31.75, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 74.41M shares, decreasing 3.33% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 4.94K shares of this stock.